ASND
Ascendis Pharma AS
227.30$
-0.2%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +186.7% | -30.4% | -62.5% | +60.7% | +200.7% | -42.0% | +56.6% | +35.2% | +14.8% | +2.2% | +37.6% | – | |
| – | +163.4% | -61.1% | +51.5% | -2.3% | +25.2% | +24.9% | +79.5% | -28.9% | +21.7% | -20.5% | +49.4% | – | |
| – | +190.9% | -25.3% | -72.2% | +90.1% | +242.9% | -47.8% | +51.7% | +51.1% | +14.0% | +5.1% | +36.5% | – | |
| – | -18.4% | -22.2% | +18.1% | -11.9% | +7.8% | +9.2% | -16.9% | -7.1% | +12.1% | -23.1% | +29.5% | – | |
| – | +2.3% | +13.0% | +0.0% | -5.8% | +15.6% | +21.4% | +10.5% | +5.7% | +20.9% | +7.6% | +18.2% | – | |
| – | -11.5% | -11.2% | +14.8% | -9.1% | +11.3% | +17.6% | -4.3% | +0.4% | +15.5% | -2.1% | +22.3% | – | |
| – | – | – | – | – | – | -27,309.4% | – | – | -10.9% | +157.3% | +151.5% | – | |
| – | +179.6% | +12.6% | -74.6% | +29.2% | +123.4% | -20.9% | -26.3% | -40.3% | +211.3% | +11.3% | -78.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +797.7% | -56.7% | -90.9% | +345.4% | +6.4% | -2.2% | +262.7% | -6.0% | +87.8% | -10,238.2% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -67.1% | – | |
| – | – | – | – | – | – | – | – | -2,400.7% | – | -40.4% | +187.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.